Pharmacy

While awareness of the problem of drug safety has grown, the industry is still trying to make a dent in solving the problem.

Two of the major causes of blindness in the United States are glaucoma and age-related macular degeneration (AMD), which often can be controlled with medication.

Generic drugs have certainly made their mark, but don't count on the same savings in the specialty market.

There are pros and cons of posting UM criteria online. Information can be helpful, but it can also open up a can of worms.

Poor adherence is the most common cause of treatment failure. Months of treatment and observation produces improvement

More specialty drugs means more management of patient needs and more cooperation

Medication adherence is the common goal of many stakeholders. Pharma is willing to help.

Patent expirations are slowing and other tools are needed to manage costs

Transparent models are fee-based, but do plan sponsors gain anything from such arrangements?

Only 20% of PDPs will offer gap coverage, and even then, most are limited to generics. House and Senate bills aim to help out.

Physicians must evaluate the use of antidepressant medications based on new guidelines from two gynecological organizations

Over the next 20 years, expect to see funky formularies and new drug benefit designs to manage costs

State of the Industry survey results

State of the Industry survey results

Hospital patients who receive dog visits require half the pain medication than patients who don't.

A Cornell study finds that the true cost of cancer drugs is 30% less than a decade ago, once longevity and quality of life are considered.

Medco Health Solutions is rumored to be the lead bidder to acquire Aetna's PBM operation.

New vaccines show some potential in therapeutic application. Historically, vaccines have been used in the prevention arenas and priimarily for children.

With plenty of potential information to be communicated among health professionals, pharmacists shouldn't be left out. For many, the pharmacist is the face of healthcare.

Like other health insurers before it, Aetna considers selling off its PBM unit.

Outcomes-based contracting enables risk sharing between plans and manufacturers while also allowing better patient adherence to regimens

Study finds that Americans have limited understanding when it comes to the cost and effectiveness of generic drugs.

While evidence-based plan designs are still evolving, they are improving health outcomes, say experts

The aging population and the huge unmet needs are fueling the focus on biologics, according to a new report from PricewaterhouseCoopers (PwC).

In the wake of healthcare reform, pharmaceutical executives help take charge.